Small study tests plerixafor for gene therapy in sickle cell

NCT ID NCT03664830

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial is testing whether the drug plerixafor can safely and effectively collect enough stem cells from people with sickle cell disease for a future gene therapy. Only 5 participants are enrolled, and the main goal is to check for side effects. If it works, it could be a step toward a treatment that controls the disease without lifelong medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

plerixafor

What this could lead to

If successful, this could pave the way for a gene therapy that helps control sickle cell disease without lifelong medication.

What could go wrong

This is a very small, early-phase safety study with only 5 participants. It may not lead to an effective treatment, and there are risks like side effects from the drug or failure to collect enough stem cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States